A Spanish consensus reportedly recommends extending continuous glucose monitoring (CGM) to people with type 2 diabetes who use basal insulin. The proposal aims to improve glucose control while reducing hypoglycemia and its effects on patients’ quality of life.
The reported signatories are SED, SEEN, SEMERGEN, SEMFyC and SEMG. The consensus reportedly links continuous monitoring with a 0.3 percentage-point overall reduction in HbA1c. Several real-world observational studies reportedly found reductions of 1.1 to 1.5 percentage points. The document also cites better Time in Range, lower glucose variability and less time spent in hypoglycemia.
The reported safety case includes a 45% fall in hospital admissions for severe hypoglycemia.
Until now, CGM had its clearest role among patients using intensive multiple-dose insulin regimens. The Spanish document reportedly extends that role to people treated with basal insulin alone or alongside other non-insulin glucose-lowering medicines. Its authors assessed the evidence using the American Diabetes Association classification before setting rules for glucose targets and follow-up. They also addressed therapeutic education and possible withdrawal of the devices.
The wider international position is more measured. The joint ADA/EASD consensus describes basal insulin as a standard way to initiate insulin therapy and recommends considering CGM primarily for people with type 2 diabetes who receive insulin.
The Spanish document reportedly identifies six priority situations: difficulty managing glucose levels; severe or recurrent hypoglycemia; occupations where an episode could endanger the patient or others; older or frail adults whose caregivers may need easier access to glucose information; people fasting for Ramadan; and patients during pregnancy.
Primary care is basic to the proposal. The document is designed to give frontline doctors a direct role in prescribing and supervising these devices, bringing complex endocrine decisions closer to ordinary medical practice.
The Spanish Diabetes Society has pointed to a practical adherence problem. Multiple insulin injections and frequent capillary testing can lead to missed doses and temporary interruptions in treatment. For patients already struggling to maintain a routine, the monitoring burden can compound the treatment burden.
The financial case rests on a model rather than observed spending. One cost-effectiveness study reviewed in the document estimates lifetime savings of €15,645 per person, attributed to reductions in acute complications worth €19,837 and chronic complications worth €4,069. The figures describe avoided complications, not a lower purchase price for the monitoring technology. The underlying study and model should be identified in the final reference list.
For the first year, the analysis estimates a direct net saving of €980 per person through fewer cases of ketoacidosis and severe hypoglycemia. Including lower microvascular and macrovascular complications, along with reduced work absenteeism, brings the projected health-system saving to nearly €2 million a year among 1,000 assessed patients. These are modelled economic projections, not observed savings.
Francisco Javier Ampudia-Blasco, endocrinologist and president of the Fundación SED, described the consensus as a step towards more proactive and personalised type 2 diabetes management. José Luis Portero, medical director of Abbott, said the cost-effectiveness evidence links more stable glucose levels with fewer acute and chronic complications, emergency visits and hospital admissions.
International guidance supports a broader role for CGM among insulin-treated people with type 2 diabetes, while noting that the strength of evidence varies by population and outcome. The reported Spanish effect sizes and priority groups are attributed to the consensus and its underlying studies.
